Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition

Investing.com - Y-mAbs Therapeutics (NASDAQ:YMAB) stock was downgraded from Buy to Hold by Truist Securities on Tuesday, following the announcement of its acquisition by SERB Pharmaceuticals. The company, which generated revenue of $88.66 million in the last twelve months, has seen its stock decline over 15% in the past week, according to InvestingPro data.

Truist Securities also lowered its price target for Y-mAbs to $8.60 from $14.00, matching the all-cash acquisition offer of $8.60 per share. The deal values Y-mAbs at $412 million and represents a 105% premium to the company’s closing share price on August 4, 2025. InvestingPro analysis shows the company maintains a strong financial position with a healthy current ratio of 4.77 and more cash than debt on its balance sheet.

The acquisition, expected to close by the fourth quarter of 2025, will transfer Y-mAbs’ commercial asset Danyelza and its development pipeline to SERB Pharmaceuticals. Danyelza is the first FDA-approved therapy for relapsed or refractory high-risk neuroblastoma.

Y-mAbs’ pipeline includes GD2 therapy targeting solid tumors and CD38 therapy in circulating tumors currently in Phase 1 development. These assets will complement SERB’s existing rare oncology portfolio.

The acquisition is expected to provide SERB with opportunities to expand Danyelza into new markets globally, leveraging the therapy’s established position in treating high-risk neuroblastoma.

In other recent news, Y-mAbs Therapeutics has been acquired by SERB Pharmaceuticals in an all-cash transaction valued at approximately $412 million. This acquisition involves a tender offer to purchase all outstanding shares of Y-mAbs for $8.60 per share. In its latest earnings report, Y-mAbs Therapeutics exceeded expectations with an earnings per share of -$0.12, compared to the forecasted -$0.1911. The company’s revenue for the first quarter of 2025 was reported at $20.9 million, closely aligning with the projected $20.84 million.

Additionally, Clear Street has reiterated a Buy rating on Y-mAbs stock and raised its price target to $17. This comes after the company provided updates on its Specific Antibody Drug Conjugates with Alpha-emitting radioisotopes (SADA) technology at a recent event. Meanwhile, H.C. Wainwright adjusted its price target for the company’s stock to $11, maintaining a Buy rating, as the firm anticipates developments in Y-mAbs’ drug pipeline. At the company’s annual shareholder meeting, David N. Gill was elected as a Class I director. These developments reflect ongoing strategic shifts and investor interest in Y-mAbs Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.